PATENT CLAIM ANALYSIS

Application Number: 16000467
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["514", "282000"]

Abstract:
The invention relates to novel strategies for the treatment of cancer patients based on a combination of an opioid receptor agonist and an anticancer compound.

Claim (Index 27):
The method according to  claim 21  wherein the anticancer agent is selected from the group consisting of:\n i. intercalating substances selected from the group consisting of anthracycline, doxorubicin, idarubicin, epirubicin,and daunorubicin; \n ii. topoisomerase inhibitors selected from the group consisting of irinotecan, topotecan, camptothecin, lamellarin D, etoposide, teniposide, mitoxantrone, amsacrine, ellipticines and aurintricarboxylic acid; \n iii. nitrosourea compounds selected from the group consisting of carmustine (BCNU), lomustine (CCNU), streptozocin; \n iv. nitrogen mustards selected from the group consisting of cyclophosphamide, mechlorethamine, uramustine, bendamustine, melphalan, chlorambucil, mafosfamide, trofosfamid and ifosfamide; \n v. alkyl sulfonates selected from the group consisting of busulfan and treosulfan; \n vi. alkylating agents selected from the group consisting of procarbazin, dacarbazin, temozolomid and thiotepa; \n vii. platinum analogues selected from the group consisting of cisplatin, carboplatin, nedaplatin, oxaliplatin, satraplatin, and triplatin tetranitrate; \n viii. Microtubule disruptive drugs selected from the group consisting of vinblastine, colcemid and nocodazole; \n ix. antifolates selected from the group consisting of methotrexate, aminopterin, dichloromethotrexat, pemetrexed, raltitrexed and pralatrexate; \n x. purine analogues selected from the group consisting of azathioprine, mercaptopurine, thioguanine, fludarabine, fludarabine phosphate, pentostatin and cladribine; \n xi. pyrimidine analogues selected from the group consisting of 5-fluorouracil, floxuridine, cytarabine, 6-azauracil, gemcitabine; \n xii. steroid hormones selected from the group consisting of gestagene, androgene, glucocorticoids, dexamethasone, prednisolone, and prednisone; \n xiii. anti-cancer antibodies selected from the group consisting of monoclonal antibodies, radioactively labeled antibodies and antibody-drug conjugates; \n xiv. anti-cancer peptides selected from the group consisting of radioactively labeled peptides and peptide-drug conjugates; \n xv. alpha, beta or gamma irradiation, electron particles, or radioactively labeled chemical compounds; and \n xvi. Taxane and Taxane analogues selected from the group consisting of paclitaxel and docetaxel.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 94.0
- Lexical Diversity: 1.08333
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['10835511', '13338809', '15920486', '13907035', '14427426']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8004865126872898
- 35 USC 102 Novelty (BERT): 0.5185057898805803
- Combined Prediction Score: 0.7722884404066188
- Mean Citation Score: 292.329026
- Max Citation Score: 308.32446
- Similarity Product: 205.0747697192824

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test